The KRAS protein has a flat, even surface that blocks standard drug molecules from attaching to it and stopping its activity.
Likely contradicted
Evidence leans against this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
The KRAS protein has a flat, even surface that blocks standard drug molecules from attaching to it and stopping its activity.
See the technical phrasing
The KRAS protein possesses a smooth, featureless surface that prevents conventional small-molecule inhibitors from binding and inhibiting its function.
KRAS has a smooth surface that normally prevents drugs from sticking, but a hidden groove near certain mutations allows specially designed molecules to latch on and lock the protein in an inactive state, stopping it from sending growth signals.
What the research says
Supports
2 studies
Study: Abstract 3448: Discovery of HYP-2A,a 2nd- generation KRASG12C inhibitor exhibits potent in vivo efficacy in drug resistant tumor models
This study provides evidence supporting the claim.
Contradicts
1 study
Study: Abstract A068: Preclinical investigation of orally bioavailable, potent pan-KRAS (ON/OFF) inhibitor JAB-23E73
This study provides evidence contradicting the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies